Innoviva, Inc. (INVA): Price and Financial Metrics

Innoviva, Inc. (INVA): $15.37

0.15 (-0.97%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

B

Add INVA to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#27 of 357

in industry

INVA Price/Volume Stats

Current price $15.37 52-week high $16.86
Prev. close $15.52 52-week low $10.64
Day low $15.31 Volume 1,311,800
Day high $15.55 Avg. volume 602,877
50-day MA $16.08 Dividend yield N/A
200-day MA $13.93 Market Cap 985.02M

INVA Stock Price Chart Interactive Chart >

INVA POWR Grades

  • Value is the dimension where INVA ranks best; there it ranks ahead of 95.01% of US stocks.
  • The strongest trend for INVA is in Value, which has been heading down over the past 26 weeks.
  • INVA ranks lowest in Momentum; there it ranks in the 18th percentile.

INVA Stock Summary

  • Over the past twelve months, INVA has reported earnings growth of -77.7%, putting it ahead of merely 17.28% of US stocks in our set.
  • As for revenue growth, note that INVA's revenue has grown -22.18% over the past 12 months; that beats the revenue growth of merely 12.49% of US companies in our set.
  • INNOVIVA INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 15.72%, greater than the shareholder yield of 89.35% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to INNOVIVA INC are DVAX, VREX, MNKD, ETSY, and JAZZ.
  • INVA's SEC filings can be seen here. And to visit INNOVIVA INC's official web site, go to www.inva.com.

INVA Valuation Summary

  • INVA's price/sales ratio is 3.5; this is 16.67% lower than that of the median Healthcare stock.
  • INVA's EV/EBIT ratio has moved up 22.3 over the prior 234 months.

Below are key valuation metrics over time for INVA.

Stock Date P/S P/B P/E EV/EBIT
INVA 2023-12-29 3.5 1.6 20.6 15.1
INVA 2023-12-28 3.6 1.7 20.8 15.3
INVA 2023-12-27 3.6 1.7 20.9 15.3
INVA 2023-12-26 3.6 1.7 20.9 15.3
INVA 2023-12-22 3.6 1.7 20.8 15.3
INVA 2023-12-21 3.6 1.7 20.8 15.3

INVA Growth Metrics

    The 4 year net income to common stockholders growth rate now stands at 162.61%.
  • The 4 year revenue growth rate now stands at 89.82%.
  • Its 2 year cash and equivalents growth rate is now at -38.41%.
INVA's revenue has moved up $223,331,000 over the prior 67 months.

The table below shows INVA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 373.216 291.208 292.58
2022-06-30 403.821 372.229 99.495
2022-03-31 396.407 377.808 187.504
2021-12-31 391.866 363.813 265.854
2021-12-31 391.866 363.813 265.854
2021-09-30 374.662 350.712 309.412

INVA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • INVA has a Quality Grade of B, ranking ahead of 77.13% of graded US stocks.
  • INVA's asset turnover comes in at 0.398 -- ranking 118th of 682 Pharmaceutical Products stocks.
  • LUMO, RETA, and SUPN are the stocks whose asset turnover ratios are most correlated with INVA.

The table below shows INVA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.398 1 0.357
2021-06-30 0.385 1 0.331
2021-03-31 0.353 1 0.337
2020-12-31 0.375 1 0.336
2020-09-30 0.389 1 0.354
2020-06-30 0.390 1 0.363

INVA Price Target

For more insight on analysts targets of INVA, see our INVA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $10.00 Average Broker Recommendation 2.5 (Moderate Sell)

Innoviva, Inc. (INVA) Company Bio


Innoviva is a biopharmaceutical company. The Company develops small molecule medicines for respiratory disease, bacterial infections, and gastrointestinal disorders. The company was founded in 1996 and is based in South San Francisco, California.


INVA Latest News Stream


Event/Time News Detail
Loading, please wait...

INVA Latest Social Stream


Loading social stream, please wait...

View Full INVA Social Stream

Latest INVA News From Around the Web

Below are the latest news stories about INNOVIVA INC that investors may wish to consider to help them evaluate INVA as an investment opportunity.

Insider Sell Alert: Marianne Zhen Offloads Shares of Innoviva Inc

In the realm of stock market movements, insider trading activity is often a significant indicator that investors keep a close eye on.

Yahoo | November 18, 2023

Innoviva, Inc. (NASDAQ:INVA) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?

Most readers would already know that Innoviva's (NASDAQ:INVA) stock increased by 2.5% over the past month. However, the...

Yahoo | November 14, 2023

Innoviva Inc (INVA) Reports Q3 2023 Financial Results: Net Income Drops to $82.0 Million

Despite a decrease in net income, the company shows promise with the launch of new therapy and positive Phase 3 data

Yahoo | November 3, 2023

Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

BURLINGAME, Calif., November 01, 2023--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the third quarter ended September 30, 2023, highlighted select corporate achievements and provided an overview of its key business initiatives.

Yahoo | November 1, 2023

Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea

GENEVA & WALTHAM, Mass., November 01, 2023--The Global Antibiotic Research & Development Partnership (GARDP), in collaboration with Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), announced today that zoliflodacin, a first-in-class antibiotic, met its primary endpoint in an unprecedented global pivotal Phase 3 clinical trial. Study investigators found that oral zoliflodacin demonstrated statistical non-inferiority of microbiological cure at the urogenital site whe

Yahoo | November 1, 2023

Read More 'INVA' Stories Here

INVA Price Returns

1-mo -6.57%
3-mo 12.27%
6-mo 20.55%
1-year 28.19%
3-year 34.47%
5-year -2.10%
YTD -4.18%
2023 21.06%
2022 -23.19%
2021 39.23%
2020 -12.50%
2019 -18.85%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!